A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis
Phase of Trial: Phase I
Latest Information Update: 22 Sep 2015
Price : $35 *
At a glance
- Drugs Pepinemab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Vaccinex
- 31 Aug 2018 Biomarkers information updated
- 31 Mar 2015 Results published in a Vaccinex media release.
- 05 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.